Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1737 - Gemcitabine and platinum- based chemotherapy in first line treatment of hepatocholangiocarcinoma : an AGEO multicenter retrospective study

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Hepatobiliary Cancers

Presenters

Maëva Salimon

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Salimon1, C. Prieux-Klotz2, D. Tougeron3, T. Lecomte4, M. Caulet4, T. Matysiak Budnik1, V. Hautefeuille5, M. Tiako-Meyo6, A. Zaanan7, Y. Touchefeu1

Author affiliations

  • 1 Imad, Department Of Gastroenterology, Nantes University Hospital, 44093 - Nantes/FR
  • 2 Department Of Gastroenterology, Cochin University Hospital, 75014 - Paris/FR
  • 3 Department Of Gastroenterology, CHU Poitiers, Jean Bernard Hôpital, 86021 - Poitiers/FR
  • 4 Department Of Gastroenterology, CHU de Tours, Hôpital Trousseau, 37170 - Chambray-lès-Tours/FR
  • 5 Department Of Gastroenterology, CHU Amiens-Picardie Site Nord, 80054 - Amiens/FR
  • 6 Department Of Gastroenterology, Hôpital Européen Georges Pomipdou, 75015 - Paris/FR
  • 7 Department Of Gastroenterology, Hopital European Georges Pompidou, 75015 - Paris/FR
More

Resources

Abstract 1737

Background

Hepatocholangiocarcinoma (cHCC-ICC) is a rare primary hepatic tumor combining features of cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC). The aim was to evaluate the overall survival (OS), progression free survival (PFS) and prognostic factors in unresectable cHCC-ICC treated by gemcitabine (gem) and platinum- based chemotherapy in first line systemic treatment.

Methods

Data from patients treated for advanced cHCC-ICC by gem and platinum- based chemotherapy in six French university hospitals between 2008 and 2016, were retrospectively collected. The diagnosis of cHCC-ICC was based on histological analysis or, in case of typical histology of ICC or HCC, on discordant CT-Scan findings and/or tumor marker (alpha-fetoprotein, carbohydrate antigen 19-9, carcinoembryonic antigen) serum levels suggesting the alternative histology. OS and PFS were estimated by Kaplan-Meier method. Prognostic factors were analyzed by Log-rank test in univariate analysis and by Cox model in multivariate analysis. Statistical analysis was performed using Graph Pad Prism 6.

Results

Forty patients were included (70% men, median age 66 years [extremes 32-88]). cHCC-ICC was histologically proven in 55% of cases. At diagnosis, twenty-three patients (57.5%) had metastatic synchronous lesion. Twenty-nine patients (72.5%) were treated by gem + oxaliplatine (GEMOX), 9(22.5%) by GEMOX + bevacizumab, 2(5%) by gem + cisplatine. Eighteen patients (45%) received second line of treatment. In the first line, patients received a median of 10 cycles of chemotherapy (extremes 1-28). RECIST1.1 criteria were reported in 35 cases: 9 patients (25.7%) had partial response, 18 (51.4%) had stable disease, 8 (22.8%) had tumor progression at first evaluation. Median PFS and OS were 9 and 15.4 months, respectively. In multivariate analysis, significant prognostic factors of poor OS were: positive serology for hepatitis B virus and/or C (HR = 1.35 IC95% [1.13-13.24] p = 0.031), serum bilirubin level > 30µmol/L (HR = 1.66 IC95% [1.57-17.54] p = 0.007), ECOG score ≥ 2 (HR = 2.46 IC95% [2.23-61.75] p = 0.004).

Conclusions

These data suggest a chemosensitivity of cHCC-ICC to gemcitabine and platinum based chemotherapy.

Clinical trial identification

Legal entity responsible for the study

Dr. Yann Touchefeu

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.